What's Happening?
Boehringer Ingelheim and Click Therapeutics have announced that their investigational digital therapeutic, CT-155, met its primary endpoint in the Phase III CONVOKE study for treating negative symptoms in schizophrenia. The study demonstrated a reduction in experiential negative symptoms when used alongside standard antipsychotic therapy. CT-155 is a prescription digital therapeutic designed to provide psychosocial interventions via smartphone applications.
Why It's Important?
The success of CT-155 represents a significant advancement in the treatment of schizophrenia, particularly for negative symptoms, which are often under-treated. Digital therapeutics offer a novel approach to mental health care, potentially improving accessibility and patient engagement. This development could pave the way for regulatory approval and wider adoption of digital health solutions, addressing unmet needs in psychiatric care.
AD
What's Next?
Detailed results from the CONVOKE study will be presented at the European College of Neuropsychopharmacology Congress in October 2025. The findings may influence future regulatory decisions and the integration of digital therapeutics into standard psychiatric treatment protocols. Stakeholders will be watching for potential FDA approval and market entry of CT-155.
